VI
ESPR icon

Versor Investments’s Esperion Therapeutics ESPR Stock Holding History

Versor Investments’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-51,800
Closed -$192K – 226
2025
Q4 		$192K Buy
+51,800
New +$167K 0.03% 567
2024
Q4 		– Sell
-26,400
Closed -$43.6K – 820
2024
Q3 		$43.6K Buy
+26,400
New +$53.3K 0.01% 743
2023
Q1 		– Sell
-37,100
Closed -$231K – 760
2022
Q4 		$231K Buy
+37,100
New +$265K 0.02% 599

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Versor Investments's ESPR Position: Q1 2026 in Review

Versor Investments sold out of Esperion Therapeutics (ESPR) in Q1 2026, closing a stake of 51,800 shares — an estimated $192K sold.

Versor Investments first reported a position in ESPR in Q4 2022 and held it in 3 quarters. The position peaked at $231K in Q4 2022. 207 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

  • Versor Investments reported no remaining Esperion Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Versor Investments sold 51,800 Esperion Therapeutics shares in Q1 2026, an estimated $192K.
  • Versor Investments first reported a position in Esperion Therapeutics in Q4 2022 and held it in 3 quarters.
  • Versor Investments's Esperion Therapeutics position peaked at $231K in Q4 2022.
  • 207 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on Versor Investments's 13F filing for Q1 2026, filed 12 May 2026.